NEWS

  • Home  >  
  • NEWS  >  
  • DISTRIBUTION AND SUPPLY AGREEMENT BETWEEN PHARMATHEN AND THE SWISS COMPANY SANTHERA PHARMACEUTICALS

NEWS

3
Μαϊ
Distribution and Supply agreement between Pharmathen and the Swiss company Santhera Pharmaceuticals
Distribution and Supply agreement between Pharmathen and the Swiss company Santhera Pharmaceuticals for the commercialization of the orphan drug Raxone (idebenone) in Greece and Cyprus.

Raxone (idebenone) is the first and only drug approved from EMA to treat patients with visual impairment due to Leber’s hereditary optic neuropathy


Pharmathen announces that it has come to an agreement with the Swiss pharmaceutical company Santhera Pharmaceuticals for the marketing of the orphan medicinal product Raxone in Greece and Cyprus.

Raxone is the first and only drug that has been approved by the European Medicines Agency EMA for the treatment of adolescents and adult patients with acute vision loss due to Leber's hereditary optic neuropathy (LHON).

Leber's Hereditary Optic Neuropathy is a mitochondrial neurodegenerative disease that attacks the optic nerve and leads to sudden loss of central vision. LHON starts painlessly in one eye, and within a few weeks the second eye is affected, resulting in a bilateral loss of central vision and legal blindness. Patients with LHON are unable to read, drive or recognize faces.

Leber's hereditary optic neuropathy is a rare disease that usually affects young and otherwise healthy individuals, and is more common in men than in women. LHON's prevalence in Europe is estimated at around 2 patients per 100,000 citizens "We are pleased to announce the completion of this strategic partnership with Santhera Pharmaceuticals, which allows us to offer an important treatment option to Greek and Cypriot patients suffering from Leber ‘s hereditary optic neuropathy," quoted Pharmathen’s President Vasileios Katsos, adding that "this partnership demonstrates our strong commitment to providing innovative solutions in the field of rare diseases."

When asked about the partnership between Santhera and Pharmathen, Giovanni Stropoli, Chief Commercial Officer, Europe and ROW from Santhera added “In Pharmathen we have a partner with the same commitment towards patients in need. Sharing the same values is a great start for a successful alliance.”